^
Association details:
| Biomarker: | EGFR G719A + EGFR S768I + PD-L1 overexpression |
|---|---|
| Cancer: | Lung Cancer |
| Drug: | AiRuiKa (camrelizumab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Case Report: Opportunities and Challenges of Immunotherapy in Heavily-Treated EGFR-Mutant Advanced Squamous Cell Lung Carcinoma After Progression on EGFR-TKIs and Chemotherapy
Published date:
02/28/2022
Excerpt:
...a 69-year-old male with a 15-year smoking history went to our hospital...SqCLC was confirmed by pathological examination and immunohistochemistry...The second NGS analysis of the whole blood sample with a large panel (Genetron Health, Beijing, China), including 824 somatic genes, suggested EGFR G719A and S768I mutations...Since an immunohistochemistry study of the right kidney metastasis showed a PD-L1 tumor proportion score (TPS) of 20% (22c3 antibody on the Dako Link-48 platform) (Figure 1B), single-agent camrelizumab (200 mg every 2 weeks) was started...The patient remained in PR after 43 cycles (Figure 3B) and was about to receive the 50th cycle of monotherapy with camrelizumab as of the time of writing of this case report (November 20, 2021), with a PFS of 24.4 months.
DOI:
https://doi.org/10.3389/fonc.2022.820408
